Monogram Orthopaedics Stock Price, News & Analysis
Company Description
Monogram Technologies Inc. (formerly traded on Nasdaq under the symbol MGRM) was an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery. According to multiple company disclosures, Monogram developed a product solution architecture intended to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, artificial intelligence and next-generation robotics.
Monogram described itself as an orthopedic robotics company working to change how joint replacement procedures are performed. Its mBôs™ precision robotic surgical system was designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. Company materials state that the goal of this approach was to support well balanced, better-fitting, bone-sparing knee replacements. Monogram initially intended to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables and other instrumentation needed for reconstructive joint replacement procedures.
Monogram obtained FDA clearance for its mPress implants and later announced FDA 510(k) clearance for the Monogram mBôs TKA System, which allowed the company to market that device subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act. The company also reported regulatory approval from India’s Central Drugs Standard Control Organization (CDSCO) to import its mBôs TKA system for a 102-patient, multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System in collaboration with Shalby Limited, described as one of the world’s largest orthopedic hospital groups.
In its public communications, Monogram stated that it believed its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods referred to as mVision, would enable more personalized knee implants, with an emphasis on bone-sparing implants and well balanced, better-fitting knee replacements. The company also indicated that it anticipated additional clinical and commercial applications for its navigated mBôs precision robot and mVision navigation beyond total knee arthroplasty.
Monogram’s technology development included a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA 510(k) clearance, and work on a fully autonomous version of the system. In a July 2025 press release, Monogram announced what it described as the world’s first fully autonomous saw-based robotic knee replacement surgery on a live patient, performed at Krishna Shalby Hospital in Ahmedabad, India, as part of its multi-center clinical trial of the Monogram TKA System. The company reported that the procedure utilized the mBôs TKA System and was intended to demonstrate the potential of autonomous, saw-based robotic total knee surgeries in real-world clinical settings.
On July 14, 2025, Zimmer Biomet Holdings, Inc., a global medical technology company, and Monogram Technologies Inc. announced that they had entered into a definitive Agreement and Plan of Merger under which Zimmer Biomet would acquire all outstanding shares of Monogram. Subsequent SEC filings, including a Form 8-K dated October 7, 2025, report that the merger closed on October 7, 2025, with a Zimmer Biomet subsidiary merging into Monogram and Monogram continuing as the surviving corporation and a wholly owned subsidiary of Zimmer Biomet.
In connection with the completion of the merger, Monogram’s common stock ceased trading on the Nasdaq Stock Market. A Form 25 filed on October 7, 2025, by Nasdaq Stock Market LLC formally notified the SEC of the removal of Monogram’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The October 7, 2025 Form 8-K notes that trading of Monogram’s common stock on Nasdaq was halted prior to the opening of trading on the closing date, and that the company intended to file a Form 15 to terminate registration of the common stock and suspend its reporting obligations.
As a result of the merger, each outstanding share of Monogram common stock (other than specified excluded or dissenting shares) was converted into the right to receive a cash amount per share and one contractual contingent value right (CVR), as described in detail in the merger-related SEC filings. The CVRs entitle holders to potential cash payments if certain product development, regulatory and revenue milestones are achieved over specified periods, as set forth in the Contingent Value Rights Agreement referenced in the filings. Following the effective time of the merger, former holders of Monogram common and preferred stock no longer had rights as stockholders of Monogram, other than the right to receive the merger consideration described in the merger agreement and related documents.
According to the company’s filings, Monogram was an emerging growth company under applicable SEC rules during its time as a public issuer. Its operations were based in Austin, Texas, as indicated by the address of its principal executive offices in SEC filings. The company’s disclosures emphasize its focus on orthopedic robotics, AI-based navigation, and patient-optimized implants, rather than on broader categories of medical devices.
Business focus and technology
Based on its public descriptions, Monogram’s core business focus centered on:
- AI-driven orthopedic robotics for total knee arthroplasty.
- Patient-optimized orthopedic implants produced using 3D printing.
- Advanced machine vision and AI navigation (mVision) integrated into robotic surgical systems.
- Robotic surgical equipment, implants and related instruments intended for reconstructive joint replacement procedures.
The company’s disclosures describe a platform approach in which robotics, imaging, AI and implant design are integrated to support personalized, bone-sparing knee replacement procedures. Monogram’s regulatory milestones, including FDA clearance for its mPress implants and the mBôs TKA System, and CDSCO approval for clinical investigation in India, are central elements of its stated business strategy.
Corporate status
Following the completion of the merger with Zimmer Biomet on October 7, 2025, Monogram Technologies Inc. became a wholly owned subsidiary of Zimmer Biomet and its common stock was delisted from Nasdaq pursuant to a Form 25 filing. The company also indicated its intention to deregister its common stock and suspend its periodic reporting obligations by filing a Form 15. For investors and researchers, the MGRM ticker now primarily represents the historical public listing of Monogram prior to its acquisition.